Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03357172 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation

Study acronym: REAL-GREFFE
StatusUnknown
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 14, 2019 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2019); last known: Recruiting
  2. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Jan 1, 2024 to Sep 30, 2026
    • Study sites: 0 to 1
    • Study completion date: Jan 1, 2026 to Sep 30, 2026
    • Start date changed from estimate of Sep 1, 2019 to Oct 1, 2019
  3. Start date: Jan 1, 2018 to Sep 1, 2019
    • Primary endpoint revised
    • Secondary endpoints: 6 to 5
    • Study title revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study concerns donors and patients receiving allogeneic stem cell haematopoietic transplantation. The aim of the study is to analyse HSC graft content in immune effector T (naive, memory, activated, exhausted) and immunoregulatory cell subtypes (Tregs, iNKT, MDSC) and correlate the results with post-transplant immune reconstitution of those different cell subtypes and clinical events (graft-versus-host-disease, relapse, infections). An ancillary study will focus on the impact of microbiota dysbiosis on post-transplant immune response and regulatory cell subsets.
Trial Details
NCT Number NCT03357172
Lead Sponsor Central Hospital, Nancy, France
Conditions
(from sponsor)		 Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment 700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov